Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

被引：191

作者：

Phillips, Elizabeth J. ^{[1
]}

Sukasem, Chonlaphat ^{[2
,3
]}

Whirl-Carrillo, Michelle ^{[4
]}

Mueller, Daniel J. ^{[5
,6
]}

Dunnenberger, Henry M. ^{[7
]}

Chantratita, Wasun ^{[8
,9
]}

Goldspiel, Barry ^{[10
]}

Chen, Yuan-Tsong ^{[11
,12
]}

Carleton, Bruce C. ^{[13
,14
]}

George, Alfred L. ^{[15
]}

Mushiroda, Taisei ^{[16
]}

Klein, Teri ^{[4
]}

Gammal, Roseann S. ^{[17
,18
]}

Pirmohamed, Munir ^{[19
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] Mahidol Univ, Ramathibodi Hosp, Fac Med, Div Pharmacogen & Personalized Med,Dept Pathol, Bangkok, Thailand

[3] Ramathibodi Hosp, Fac Med, Somdech Phra Debaratana Med Ctr, Lab Pharmacogen, Bangkok, Thailand

[4] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA

[5] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada

[6] Univ Toronto, Dept Psychiat & Pharmacol & Toxicol, Toronto, ON, Canada

[7] NorthShore Univ HealthSyst, Ctr Mol Med, Evanston, IL USA

[8] Mahidol Univ, Ramathibodi Hosp, Fac Med, Virol Lab,Dept Pathol, Bangkok, Thailand

[9] Mahidol Univ, Ramathibodi Hosp, Ctr Med Genom, Bangkok, Thailand

[10] NIH, Pharm Dept, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA

[11] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan

[12] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA

[13] Univ British Columbia, Fac Med, Dept Pediat, Div Translat Therapeut, Vancouver, BC, Canada

[14] BC Childrens Hosp, Res Inst, Vancouver, BC, Canada

[15] Northwestern Univ, Dept Pharmacol, Feinberg Sch Med, Chicago, IL 60611 USA

[16] RIKEN, Ctr Integrat Med Sci, Lab Pharmacogen, Yokohama, Kanagawa, Japan

[17] MCPHS Univ, Dept Pharm Practice, Boston, MA USA

[18] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

[19] Univ Liverpool, Dept Pharmacol, Liverpool, Merseyside, England

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷 / 04期

基金：

加拿大健康研究院; 英国医学研究理事会; 加拿大创新基金会; 美国国家卫生研究院;

关键词：

STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ADVERSE DRUG-REACTIONS; CYTOTOXIC T-CELLS; HLA-B-ASTERISK-1502; ALLELE; B GENOTYPE; HYPERSENSITIVITY REACTIONS; CUTANEOUS REACTIONS; JAPANESE PATIENTS; THAI POPULATION;

D O I：

10.1002/cpt.1004

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.

引用

页码：574 / 581

页数：8

共 50 条

[21] Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
Caudle, Kelly E.
Klein, Teri E.
Hoffman, James M.
Mueller, Daniel J.
Whirl-Carrillo, Michelle
Gong, Li
McDonagh, Ellen M.
Sangkuhl, Katrin
Thorn, Caroline F.
Schwab, Matthias
Agundez, Jose A. G.
Freimuth, Robert R.
Huser, Vojtech
Lee, Ming Ta Michael
Iwuchukwu, Otito F.
Crews, Kristine R.
Scott, Stuart A.
Wadelius, Mia
Swen, Jesse J.
Tyndale, Rachel F.
Stein, C. Michael
Roden, Dan
Relling, Mary V.
Williams, Marc S.
Johnson, Samuel G.
CURRENT DRUG METABOLISM, 2014, 15 (02) : 209 - 217
[22] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2C9andHLA-BGenotypes and Phenytoin Dosing: 2020 Update
Karnes, Jason H.
Rettie, Allan E.
Somogyi, Andrew A.
Huddart, Rachel
Fohner, Alison E.
Formea, Christine M.
Ta Michael Lee, Ming
Llerena, Adrian
Whirl-Carrillo, Michelle
Klein, Teri E.
Phillips, Elizabeth J.
Mintzer, Scott
Gaedigk, Andrea
Caudle, Kelly E.
Callaghan, John T.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (02) : 302 - 309
[23] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing
Gammal, R. S.
Court, M. H.
Haidar, C. E.
Iwuchukwu, O. F.
Gaur, A. H.
Alvarellos, M.
Guillemette, C.
Lennox, J. L.
Whirl-Carrillo, M.
Brummel, S. S.
Ratain, M. J.
Klein, T. E.
Schackman, B. R.
Caudle, K. E.
Haas, D. W.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (04) : 363 - 369
[24] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
Goetz, Matthew P.
Sangkuhl, Katrin
Guchelaar, Henk-Jan
Schwab, Matthias
Province, Michael
Whirl-Carrillo, Michelle
Symmans, W. Fraser
McLeod, Howard L.
Ratain, Mark J.
Zembutsu, Hitoshi
Gaedigk, Andrea
van Schaik, Ron H.
Ingle, James N.
Caudle, Kelly E.
Klein, Teri E.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) : 770 - 777
[25] Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
Crews, K. R.
Gaedigk, A.
Dunnenberger, H. M.
Leeder, J. S.
Klein, T. E.
Caudle, K. E.
Haidar, C. E.
Shen, D. D.
Callaghan, J. T.
Sadhasivam, S.
Prows, C. A.
Kharasch, E. D.
Skaar, T. C.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (04) : 376 - 382
[26] THE CLINICAL PHARMACOGENETICS IMPLEMENTATION CONSORTIUM (CPIC) CLINICAL PRACTICE GUIDELINES
Caudle, Kelly
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : 1063 - 1064
[27] The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later
Relling, Mary V.
Klein, Teri E.
Gammal, Roseann S.
Whirl-Carrillo, Michelle
Hoffman, James M.
Caudle, Kelly E.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (01) : 171 - 175
[28] Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing
Hershfield, M. S.
Callaghan, J. T.
Tassaneeyakul, W.
Mushiroda, T.
Thorn, C. F.
Klein, T. E.
Lee, M. T. M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (02) : 153 - 158
[29] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
Birdwell, K. A.
Decker, B.
Barbarino, J. M.
Peterson, J. F.
Stein, C. M.
Sadee, W.
Wang, D.
Vinks, A. A.
He, Y.
Swen, J. J.
Leeder, J. S.
van Schaik, R. H. N.
Thummel, K. E.
Klein, T. E.
Caudle, K. E.
MacPhee, I. A. M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (01) : 19 - 24
[30] Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group
Bank, P. C. D.
Caudle, K. E.
Swen, J. J.
Gammal, R. S.
Whirl-Carrillo, M.
Klein, T. E.
Relling, M. V.
Guchelaar, H-J
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (04) : 599 - 618

← 1 2 3 4 5 →